Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Yea... (7.5% to 8.5% of EBTA 7.5% to 8.5% of...)

Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance

Date:11/10/2008

7.5% to 8.5% of EBTA 7.5% to 8.5% of EBTA

GAAP Net Income $129 to $142 $133 to $146

Cash Net Income ("CNI") $326 to $339 $346 to $359 (5)

CNI per share (6) $1.30 to $1.35 $1.38 to $1.43 (5)

(1) Revised guidance includes the expected impact of generic competition

introduced in the second quarter of 2008 for SARAFEM and DOVONEX

solution. Guidance does not account for the impact of any future

new licensing agreements.

(2) Total SG&A expense does not include any amount that may be payable

in connection with the potential settlement of our outstanding

legal actions.

(3) The guidance includes $2.5 million related to potential third

party R&D milestone payments.

(4) The total 2008 tax provision is estimated as a percentage of

earnings before taxes and book amortization ("EBTA").

(5) A reconciliation of 2008 GAAP net income to CNI adds back the

expected after tax impact of the amortization of intangibles ($205M)

and the expected after tax impact of deferred financing fees ($8M).

(6) CNI per share is based on 251.0 million fully diluted Class A shares.

Post Your Comments:

Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Yea...(7.5% to 8.5% of EBTA 7.5% to 8.5% of...),Health